Abstract

Despite reaching an epidemic status worldwide, metabolic disorders, notably diabetes, still miss efficient and specific therapeutic strategies because of their multifactorial origin. SHP2 is a ubiquitous tyrosine phosphatase that regulates major signalling pathways (e.g. MAPK, PI3K) in response to many growth factors. The inventors evaluate whether chronic inhibition of SHP2 could improve insulin sensitivity in animal models. Obese diabetic mice were thus treated by gavage (50 mg/kg/day). And the inventors note a significant improvement in the glucose tolerance of the treated animals compared to their control, with a decreased fasting blood glucose, without any change in weight or body composition. Accordingly, the present invention relates to use of SHP2 inhibitors for the treatment of insulin resistance.

IPC Classes  ?

• A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Abstract

222; - one or more organic acids selected from monocarboxylic acids comprising at least 10 carbon atoms and polycarboxylic acids; and - one or more gelling agents. The invention also relates to the use of this composition for disassembling a structure comprising at least two elements secured to one another by means of an adhesive joint, and to a method for disassembling such a structure.

Abstract

The present invention relates to a method for producing a substoichiometric oxygen layer from titanium, vanadium, tungsten or molybdenum oxide on a substrate by magnetron sputtering a target in a chamber, the method being characterised in that the target consists of titanium, vanadium, tungsten or molybdenum oxide and in that it comprises the steps of: a) creating a vacuum in the chamber and adding an inert gas to same; b) simultaneously applying a first radiofrequency potential to the target and a second radiofrequency potential to the substrate so as to generate, in the chamber, a plasma that is suitable for simultaneously i) sputtering the target to deposit a layer of the titanium, vanadium, tungsten or molybdenum oxide on the substrate; and ii) sputtering the layer of titanium, vanadium, tungsten or molybdenum oxide deposited on the substrate to remove oxygen atoms from the layer.

IPC Classes  ?

• C23C 14/35 - Sputtering by application of a magnetic field, e.g. magnetron sputtering
• C23C 14/08 - Oxides
• C23C 14/34 - Sputtering
• C23C 14/50 - Substrate holders

Abstract

A process for manufacturing an abradable layer, includes compressing a powder composition including at least micrometric ceramic particles having a number-average form factor greater than or equal to 3, a mass content of said micrometric ceramic particles in the powder composition being greater than or equal to 85%, the form factor of a particle being defined as the ratio [largest dimension of the particle]/[largest cross-sectional dimension of the particle], and sintering the powder composition thus compressed to obtain the abradable layer, wherein a temperature imposed during sintering, the sintering time and the compression pressure applied are selected so as to obtain a volume porosity rate of the abradable layer greater than or equal to 20%.

IPC Classes  ?

• C23C 24/08 - Coating starting from inorganic powder by application of heat or pressure and heat
• B82Y 40/00 - Manufacture or treatment of nanostructures
• C04B 41/00 - After-treatment of mortars, concrete, artificial stone or ceramicsTreatment of natural stone
• C04B 41/45 - Coating or impregnating
• F01D 11/12 - Preventing or minimising internal leakage of working fluid, e.g. between stages for sealing space between rotor blade tips and stator using a rubstrip, e.g. erodible, deformable or resiliently biased part

Abstract

Ischemic conditions are a leading cause of death for both men and women, Ischemia, a condition characterized by reduced blood flow and oxygen to an organ. Re-establishment of blood flow, or reperfusion, and re-oxygenation of the affected area following an ischemic episode is critical to limit irreversible damage. However, reperfusion also associates potentially damaging consequences. For instance, increased vascular permeability is an important contributor to edema and tissue damage following ischemic events. Here the inventors shows that genetic inhibition of PI3K-C2β reduces cerebral infarction in two ischemic/reperfusion (I/R) models and improves neurological outcome. The genetic inhibition stabilizes the blood-brain barrier (BBB) after ischemic stroke and reduces inflammation. Accordingly, the present invention relates to a method for the preservation of vascular endothelial cell barrier integrity in a patient in need thereof comprising administering to the subject a therapeutically effective amount of a PI3KC2β inhibitor.

IPC Classes  ?

• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing

Abstract

A method for forming a cathodic protection coating on a substrate forming a turbomachine part, includes deposition, on the substrate, of particles for cathodic protection of the substrate, this deposition being performed by electrophoresis from an organic electrolyte including the particles, and forming an inorganic matrix in pores of the deposit of particles produced in this way, including impregnating the deposit with an impregnation composition, drying heat treatment of the deposit impregnated by the impregnation composition, and densifying the deposit by mechanical compacting, after the drying heat treatment, in order to make the deposit electrically conductive.

IPC Classes  ?

• C25D 13/02 - Electrophoretic coating characterised by the process with inorganic material
• C25D 13/14 - TubesRingsHollow bodies
• C25D 13/22 - Servicing or operating

Abstract

Process for detecting and identifying micropeptides (miPEPs) encoded by a nucleotide sequence contained in the sequence of the primary transcript of a microRNA and use thereof for modulating gene expression.

IPC Classes  ?

• C07K 14/415 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from plants
• A01N 37/46 - N-acyl derivatives
• A01N 57/16 - Biocides, pest repellants or attractants, or plant growth regulators containing organic phosphorus compounds having phosphorus-to-oxygen bonds or phosphorus-to-sulfur bonds containing heterocyclic radicals
• A01N 65/00 - Biocides, pest repellants or attractants, or plant growth regulators containing material from algae, lichens, bryophyta, multi-cellular fungi or plants, or extracts thereof
• A01N 65/08 - Magnoliopsida [dicotyledons]
• A01N 65/20 - Fabaceae or Leguminosae [Pea or Legume family], e.g. pea, lentil, soybean, clover, acacia, honey locust, derris or millettia
• A01N 65/28 - Myrtaceae [Myrtle family], e.g. teatree or clove
• A01N 65/44 - Poaceae or Gramineae [Grass family], e.g. bamboo, lemon grass or citronella grass
• A61K 38/00 - Medicinal preparations containing peptides
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• C07K 5/10 - Tetrapeptides
• C07K 5/103 - Tetrapeptides the side chain of the first amino acid being acyclic, e.g. Gly, Ala
• C07K 7/06 - Linear peptides containing only normal peptide links having 5 to 11 amino acids
• C07K 7/08 - Linear peptides containing only normal peptide links having 12 to 20 amino acids
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression
• C12N 15/82 - Vectors or expression systems specially adapted for eukaryotic hosts for plant cells
• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
• C12Q 1/6895 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for plants, fungi or algae

Abstract

The present invention relates to the field of cancer diagnostic methods for classifying cancer patients using a measure of the distribution of markers of DNA structure alterations within tumor genomic DNA sequence. The inventors have observed, in sarcomas, such as leiomyosarcoma, that the distribution of breakpoints within a set of selected transcription-associated chromosomal instability elements and a set of selected replication-associated chromosomal instability elements can be used to classify patients in groups according to a level of genome instability, which may be representative of a cancer evolution, a risk of occurrence of metastasis, a survival rate, or a sensibility to a cancer treatment. The present invention also relates to machine learning and trained classifiers for classifying patients having a cancer based upon a distribution of genomic DNA structure alterations or variations.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
• G16B 40/00 - ICT specially adapted for biostatisticsICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
• G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment

Abstract

A method for manufacturing an abradable layer and a substrate coated with this layer, may include: preparing a powder composition including at least ceramic particles and an inorganic filler having a lamellar crystallographic structure, the volume content of the inorganic filler in the powder composition being in a range of from 1 to 75%; compressing the powder composition; and sintering the powder composition thus compressed in order to obtain the abradable layer.

IPC Classes  ?

• C04B 35/48 - Shaped ceramic products characterised by their compositionCeramic compositionsProcessing powders of inorganic compounds preparatory to the manufacturing of ceramic products based on oxides based on zirconium or hafnium oxides or zirconates or hafnates
• C04B 35/50 - Shaped ceramic products characterised by their compositionCeramic compositionsProcessing powders of inorganic compounds preparatory to the manufacturing of ceramic products based on rare earth compounds
• C04B 35/626 - Preparing or treating the powders individually or as batches
• C04B 35/645 - Pressure sintering
• C23C 24/08 - Coating starting from inorganic powder by application of heat or pressure and heat

Abstract

Brown and beige adipose tissues (BAT) dissipate energy as heat thanks to their high mitochondrial content equipped with uncoupling protein­1 (UCP1). Therefore, brown and beige adipocytes are promising cell targets to counteract metabolic diseases. Nevertheless, current studies on pharmaceutical activation of BAT are still impeded by the lack of relevant human in vitro BAT model. The models available to date poorly reflect the complex environment in which cells reside in vivo. A solution to overcome this problem is to provide a pre­vascularized human brown/beige adipose tissue transplant clinically relevant in size and functions. Accordingly, the present invention proposes an in vitro method for preparing a 3D pre­vascularized brown/beige adipose tissue construct, the 3D pre­vascularized brown/beige adipose tissue construct thus prepared, an intermediate construct obtained during this preparation and different uses thereof.

IPC Classes  ?

• C12N 5/077 - Mesenchymal cells, e.g. bone cells, cartilage cells, marrow stromal cells, fat cells or muscle cells
• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues

Abstract

A device including a first portion, a second portion, a first contact and a second contact, the first portion being made of a semiconductor having a first doping, the second portion being made of a semiconductor having a second doping different than the first, the first portion and the second portion forming a p/n junction including a depletion zone in the first portion, the contacts being configured so that when an electric voltage (V1) is applied between the contacts, a dimension of the depletion zone depends on a value of the electric voltage, an ionization energy being defined for dopants of the second portion. The device includes an emitter generating a radiation having an energy greater than the ionization energy and illuminating the second portion with the radiation.

IPC Classes  ?

• H01L 33/00 - SEMICONDUCTOR DEVICES NOT COVERED BY CLASS - Details thereof
• H01L 33/34 - Materials of the light emitting region containing only elements of group IV of the periodic system

Abstract

The present invention relates to methods and pharmaceutical compositions for the treatment of post-operative cognitive dysfunction. In particular, the present invention relates to a method of treating post-operative cognitive dysfunction in a subject in need thereof comprising administering to the subject a therapeutically effective amount of an APJ receptor agonist.

IPC Classes  ?

• A61K 38/22 - Hormones
• A61K 31/015 - Hydrocarbons carbocyclic
• A61K 31/02 - Halogenated hydrocarbons
• A61K 31/08 - Ethers or acetals acyclic, e.g. paraformaldehyde
• A61K 33/00 - Medicinal preparations containing inorganic active ingredients
• A61P 23/00 - Anaesthetics
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

A binder composition in dry weight percentage comprising a) between 1% and 30% of Portland cement, lime or a mixture thereof, b) between 1% and 40% of ground granulated blast furnace slag, c) between 20% and 50% of at least one pozzolanic material, d) between 20% and 65% of at least one filler, e) between 0.5% and 10%, relative to the total weight of components a, b, c, and d, of at least one activator, f) between 0.05% and 1.5%, relative to the total weight of components a, b, c and d, of at least one water reducer polymer, the filler being a mixture between 10% and 90% in weight of particles having a d50≥0.05 μm and <8 μm, and between 10% and 90% in weight of particles having a d50≥8 μm and <200 μm, the filler mixture weight percentages in respect to total weight of the filler.

IPC Classes  ?

• C04B 28/12 - Hydraulic lime
• C04B 14/28 - Carbonates of calcium
• C04B 22/14 - Acids or salts thereof containing sulfur in the anion, e.g. sulfides
• C04B 28/08 - Slag cements
• C04B 103/10 - Accelerators
• C04B 103/30 - Water reducers, plasticisers, air-entrainers

Abstract

The present invention provides cationic peptoid/N-substituted peptidic copolymers, and pharmaceutical compositions thereof, as described generally and in subclasses herein, which compounds are useful for the treatment of microbial infections.

IPC Classes  ?

• A61L 27/54 - Biologically active materials, e.g. therapeutic substances
• A61L 27/22 - Polypeptides or derivatives thereof
• C07K 7/64 - Cyclic peptides containing only normal peptide links
• C07K 14/00 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof

Abstract

A binder composition in dry weight percentage comprises a) between 1% and 30% of at least one lime source, b) between 5% and 75% of ground granulated blast furnace slag, (c) between 20% and 90% of at least one filler, (d) between 0.1% and 5% of SO3−, e) between 0.1% and 1% of at least one water reducer polymer, f) between 0% and 2%, relative to the total weight of components a, b and c, of at least one activator different from d, the weights of d, e, f relative to the total weight of components a, b, c, said ground granulated blast furnace slag and the filler each being a mixture of two differently sized particles, the different sizes based on d50 and range of between 1 μm and 5 μm and >5 μm for the slag and between 0.05 μm and <8 μm and ≥8 μm and <200 μm for the filler.

IPC Classes  ?

• C04B 28/08 - Slag cements
• C04B 40/06 - Inhibiting the setting, e.g. mortars of the deferred action type containing water in breakable containers

Abstract

The Inventors herein demonstrate that CD39 is a relevant therapeutic target in B-cell lymphoma, in particular Follicular Lymphoma (FL), Diffuse Large B-Cell Lymphoma (DLBCL) and Mantle Cell Lymphoma (MCL). They also demonstrate that CD39 potentiate anti-CD20 monoclonal antibody therapy and/or anti-PD1 monoclonal antibody therapy, and that ENTPD1 overexpression is correlated with poor prognosis in FL patients. Accordingly, the present invention relates to a method of treating a B-cell lymphoma in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a CD39 inhibitor.

IPC Classes  ?

• A61P 35/00 - Antineoplastic agents
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

Abstract

The invention relates to a protecting and connecting device (10) of at least one stoma site emerging out of a patient's skin, the protecting and connecting device comprising: • - a shield (30) that comprises a wall (31) delimited by a peripheral outline (32), the shield generating an inside compartment protecting the site of said stoma, • - an outskirt (40) surrounding at least partially peripheral outline of the shield, wherein a lower face of the outskirt comprises an adhesive layer for sealing the shield onto the patient's skin, and • - at least one receiving hole (50, 51) through the wall of the shield, said receiving hole defining a passage for at least one probe (60, 61). According to the invention, the protecting and connecting device comprises a tab (70) providing a grasp mean for unsealing the shield from the patient's skin.

IPC Classes  ?

• A61F 5/44 - Devices worn by the patient for reception of urine, faeces, catamenial or other dischargeColostomy devices
• A61F 5/445 - Colostomy devices

Abstract

The present invention relates to new dendrimers with thiophosphoramidate units and derivatives, their preparation method and their use.

IPC Classes  ?

• C07F 9/6593 - 1,3,5-Triaza-2,4,6-triphosphorines
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]

Abstract

The invention relates to a method for producing an abradable ceramic composite coating on a substrate, the method comprising: obtaining (E1) a composition (30) in powder form comprising a matrix powder and a ceramic filler hydrated precursor powder having a lamellar crystallographic structure, wherein the ceramic filler powder represents from 5 to 40% of the combined volume of the matrix powder and the ceramic filler powder; compressing the prepared powder composition at a pressure greater than 150 MPa; and a step of reactive sintering (E2) the obtained powder composition, during which the pressure is maintained at a temperature of less than 550°C, and the particles of the matrix powder in the sintered powder composition have an aspect ratio of 2 or greater. The invention also relates to an abradable ceramic coating obtained according to the method. The invention also relates to a superalloy part for a turbomachine, for example a turbine part, comprising such a coating.

IPC Classes  ?

• C04B 41/00 - After-treatment of mortars, concrete, artificial stone or ceramicsTreatment of natural stone
• C04B 35/488 - Composites
• C04B 35/486 - Fine ceramics
• C04B 35/622 - Forming processesProcessing powders of inorganic compounds preparatory to the manufacturing of ceramic products
• C04B 35/645 - Pressure sintering
• C04B 38/00 - Porous mortars, concrete, artificial stone or ceramic warePreparation thereof
• C04B 41/52 - Multiple coating or impregnating
• C04B 41/87 - Ceramics
• C04B 41/89 - Coating or impregnating for obtaining at least two superposed coatings having different compositions
• B32B 18/00 - Layered products essentially comprising ceramics, e.g. refractory products
• F01D 11/12 - Preventing or minimising internal leakage of working fluid, e.g. between stages for sealing space between rotor blade tips and stator using a rubstrip, e.g. erodible, deformable or resiliently biased part
• C23C 24/08 - Coating starting from inorganic powder by application of heat or pressure and heat
• F01D 25/00 - Component parts, details, or accessories, not provided for in, or of interest apart from, other groups
• C04B 111/00 - Function, property or use of the mortars, concrete or artificial stone

Abstract

The invention relates to an angular positioning module (1) for a positioning system for an optical bench, the angular positioning module (1) comprising: a fixed frame (5); a rotating shaft (7); a rotary motor (11); a transmission device (17) being provided with a pulley (19) mounted on the output rod (13) of the rotary motor (11) so as to be coupled in rotation therewith, with a wheel (21) mounted on the rotating shaft (7) so as to be coupled in rotation therewith, and with a cable wound on the one hand around the pulley (19) and on the other hand around the wheel (21) such that the pulley (19) and the wheel (21) are connected by two separate strands of the cable, the rotation of the pulley (19) causing the winding of a first strand and the simultaneous unwinding of a separate second strand around the pulley (19), and vice versa.

IPC Classes  ?

• G02B 7/00 - Mountings, adjusting means, or light-tight connections, for optical elements
• F16H 19/06 - Gearings comprising essentially only toothed gears or friction members and not capable of conveying indefinitely-continuing rotary motion for interconverting rotary motion and reciprocating motion comprising an endless flexible member

Abstract

The invention relates to a device (100) for controlling and protecting a power transistor (102), comprising: - a nominal switching circuit (103) for the transistor; - a short-circuit detection circuit (105) which keeps the transistor in the conducting state and detects an increase or decrease in the voltage VGS of the transistor relative to reference voltages representative of a short-circuit of the transistor; - a protection circuit (107) which discharges the gate of the transistor after the detection of a short-circuit; and - a circuit (106) for measuring and controlling the nominal switching circuit, the short-circuit detection circuit and the protection circuit.

IPC Classes  ?

• H03K 17/0812 - Modifications for protecting switching circuit against overcurrent or overvoltage without feedback from the output circuit to the control circuit by measures taken in the control circuit
• H03K 17/18 - Modifications for indicating state of switch
• H03K 17/16 - Modifications for eliminating interference voltages or currents

IPC Classes  ?

• C12N 9/12 - Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
• C12N 15/90 - Stable introduction of foreign DNA into chromosome

Abstract

attPattP site of the bacteriophage mv4 and to a kit for such site-specific recombination. The kit can be used to transform procaryote hosts to integrate any polynucleotide sequence of interest.

IPC Classes  ?

• C12N 9/12 - Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
• C12N 15/90 - Stable introduction of foreign DNA into chromosome

Abstract

A method for impregnating an oxide fibre roving with a matrix of alumina and silica includes a introducing an oxide fibre roving into an impregnation bath, wherein the impregnation bath is prepared by sol-gel process and includes a silica precursor in the form of a hybrid polymeric sol, an alumina precursor in the form of a colloidal sol and ceramic particles.

IPC Classes  ?

• C04B 35/628 - Coating the powders
• C04B 35/117 - Composites
• C04B 35/14 - Shaped ceramic products characterised by their compositionCeramic compositionsProcessing powders of inorganic compounds preparatory to the manufacturing of ceramic products based on oxides based on silica
• C04B 35/18 - Shaped ceramic products characterised by their compositionCeramic compositionsProcessing powders of inorganic compounds preparatory to the manufacturing of ceramic products based on oxides based on silicates other than clay rich in aluminium oxide
• C04B 35/634 - Polymers
• C04B 35/80 - Fibres, filaments, whiskers, platelets, or the like

Abstract

Rheumatoid arthritis (RA) is the most prevalent chronic autoimmune inflammatory rheumatism. Its pathophysiology is largely dependent on TNF. Severe RA as well as several other inflammatory and autoimmune diseases are treated with TNF inhibitors (TNFi). However, to date only 30-50% achieve low disease activity or remission with this treatment regimen and some patients experience secondary non-response or relapse. Herein, the inventors evaluated by RT-qPCR the mRNA expression of CD36, which was already described to be regulated by TNFi5, some specific NRF2 target genes (FBX030, GABARA, LBR, MAFG, OSGIN1, HMOX1), which play a role in the anti-oxidative stress response or anti-inflammatory pathway, and the expression of CSMD1, an anti-inflammatory gene that we observed as up-regulated by all TNFi. Interestingly, they observed 2 different subsets of healthy donors: (i) donors in which TNFi stimulation increased mRNA of target genes in macrophages and (ii) conversely donors with no significant upregulation in transcription of these target genes. Then they classified donors two different status, “activators” or “non-activators” of tmTNF reverse signaling after TNFi stimulation, which correlates to clinically responder and non-responders to TNFi. Thus, based on all these observations, they developed an in vitro method for predicting the response to TNF inhibitors in patient in need thereof.

IPC Classes  ?

• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
• C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A61P 19/02 - Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis

Abstract

The response of subjects suffering from cancer to MAPK inhibitors is dramatically impaired by secondary resistances and rapid relapse. So far, the molecular mechanisms driving these resistances are not completely understood. The inventors show that expression of 10 SLITRK6 (SLIT and NTRK-like family, member 6) is induced by a MAPK inhibitor (e.g. Vemurafenib) and the inhibition of its induction in presence of the MAPK inhibitor induces synthetic lethality. Thus, the only inhibition of SLITRK6 by an inhibitor ot activity or expression should potentiate the antitumor effect of the MAPK inhibitors and avoid the emergence of a resistance to those compounds. Furthermore the specific expression of 15 SLITRK6 also paves the way of strategies based on depletion of the residual cancer cells by targeting them with anti-SLITRK6 antibodies capable of mediating ADCC or antibody-drug conjugates binding to SLITRK6.

IPC Classes  ?

• A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
• A61P 35/00 - Antineoplastic agents
• A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
• A61K 38/08 - Peptides having 5 to 11 amino acids
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

Abstract

The invention relates to a method for recycling a prepreg comprising at least one epoxy resin and reinforcements, the method comprising the following consecutive steps: (1) bringing the prepreg into contact with a composition comprising one or more organic carbonates chosen from among dialkyl carbonates and alkylene carbonates; (2) separating the solid phase comprising the reinforcements R from the liquid phase resulting from step (1); and (3) collecting the liquid phase resulting from step (2). The invention also relates to the use of this composition for recycling such a prepreg.

IPC Classes  ?

• C08J 11/08 - Recovery or working-up of waste materials of polymers without chemical reactions using selective solvents for polymer components
• B29B 17/02 - Separating plastics from other materials
• B08B 3/00 - Cleaning by methods involving the use or presence of liquid or steam
• C03C 25/70 - Cleaning, e.g. for reuse

Abstract

The invention relates to the use of a composition comprising: an aqueous hydrogen peroxide solution, one or more organic carbonates chosen from dialkyl carbonates and alkylene carbonates, one or more lactones, and either one or more organic acids chosen from monocarboxylic acids comprising at least 10 carbon atoms and polycarboxylic acids, or one or more mineral acids chosen from sulphuric acid and phosphoric acid, or one or more alkali metal or alkaline earth metal hydroxides (d2) for recycling a material M obtained from an epoxy resin. The invention also relates to a method for recycling such a material using this composition, as well as to a specific composition.

IPC Classes  ?

• C08J 11/14 - Recovery or working-up of waste materials of polymers by chemically breaking down the molecular chains of polymers or breaking of crosslinks, e.g. devulcanisation by treatment with steam or water
• C08J 11/16 - Recovery or working-up of waste materials of polymers by chemically breaking down the molecular chains of polymers or breaking of crosslinks, e.g. devulcanisation by treatment with inorganic material
• C08J 11/26 - Recovery or working-up of waste materials of polymers by chemically breaking down the molecular chains of polymers or breaking of crosslinks, e.g. devulcanisation by treatment with organic material by treatment with organic oxygen-containing compounds containing carboxylic acid groups, their anhydrides or esters
• B29B 17/02 - Separating plastics from other materials

Abstract

The present invention concerns a method for characterizing a geological reservoir of interest, the method comprising the training of an artificial intelligence model according to a training technique applied to a training database to obtain a trained model, the trained model predicting the spatiotemporal evolution over a period of time of flow parameter(s) for a geological reservoir of interest when a set of input data relative to the geological reservoir of interest are inputted in the trained model, the set of input data comprising initial values of each flow parameter for the geological reservoir of interest and values of geological features for said geological reservoir of interest, the artificial intelligence model being a neural network having neural parameters.

IPC Classes  ?

• E21B 43/00 - Methods or apparatus for obtaining oil, gas, water, soluble or meltable materials or a slurry of minerals from wells
• G01V 99/00 - Subject matter not provided for in other groups of this subclass
• G06F 30/20 - Design optimisation, verification or simulation
• G06N 3/04 - Architecture, e.g. interconnection topology

Abstract

Anthracyclines such as doxorubicin are chemotherapeutic molecules are also widely incorporated in many chemotherapy protocols. However, their clinical use is still limited by time- and dose-dependent cardiotoxicity. Herein the inventors have determined the therapeutic potential of acidic nanoparticles (NPs) in doxo-treated cardiac cells. In particular, they have identified a set of grafted nanoparticles as non-toxic and which rapidly internalize into lysosomes in cardiac cells. Such NPs improve lysosomal acidification and autophagic flux blockade caused by bafilomycin A1, chloroquine and doxorubicin, resulting in reduced oxidative stress, preserved mitochondrial integrity and improved cell survival. Thus, the invention relates to a biocompatible and biodegradable nanoparticle having a diameter of 100 nm or less, wherein the nanoparticle is selected from: a poly(lactic-co-glycolic acid) (PLGA) nanoparticle, a poly(lactic acid) (PLA) nanoparticle, a poly(glutamic acid) (PGA) nanoparticle, a polycaprolactone (PCL) nanoparticle, and/or a polyester nanoparticle; for use in a method for treating or preventing a cardiomyopathy or anthracycline cytotoxicity.

IPC Classes  ?

• A61K 9/16 - AgglomeratesGranulatesMicrobeadlets
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 31/704 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin, digitoxin
• A61P 9/04 - Inotropic agents, i.e. stimulants of cardiac contractionDrugs for heart failure

Abstract

Vaccines for preventing or treating diabetes, obesity and complications thereof are provided. The vaccines comprise at least one active agent such as attenuated Porphyromonas gingivalis, inactivated Porphyromonas gingivalis, a subunit of Porphyromonas gingivalis, a recombinant or isolated immunogenic polypeptide or peptide from Porphyromonas gingivalis or a cDNA from Porphyromonas gingivalis.

IPC Classes  ?

• A61K 39/02 - Bacterial antigens
• A61K 39/114 - Fusobacterium
• C07K 16/12 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from bacteria
• A61P 1/02 - Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Abstract

The invention relates to a method for oxidising organic compounds contained in an anoxic liquid medium, comprising an upper surface above which there is a gaseous medium containing an oxidising compound, also known as an electron acceptor, wherein the following successive steps are carried out: a) bringing the anoxic liquid medium into contact with a three-dimensional porous support, wherein: - the support comprises a first portion, referred to as the unsubmerged portion, which is located above the upper surface of the liquid medium, in contact with the gaseous medium, and a second portion, referred to as the submerged portion, which is located below the surface of the liquid medium; - the volume of the unsubmerged portion represents at least 20% of the total volume of the support; - at least 80%, preferably at least 90%, and more preferably all (100%) of the internal surface of the pores and of the external surface of the porous support is covered with a biofilm which does not block the pores; b) moving, in the pores of the porous support, the liquid medium containing the organic compounds from the submerged portion into the unsubmerged portion of the support by means of capillary rise; c) bringing the organic compounds in the emerged portion of the support into contact with the oxidising compound, also known as an electron acceptor, which oxidising compound, also known as an electron acceptor, oxidises the organic compounds by means of biofilm-catalysed oxidation.

IPC Classes  ?

• B08B 1/00 - Cleaning by methods involving the use of tools
• C02F 11/06 - Treatment of sludgeDevices therefor by oxidation
• C25B 3/25 - Reduction

Abstract

Polypeptides belonging to the family of late proteins of the cornified envelope (LCE), fragments of the polypeptide, isolated nucleotide sequences encoding the polypeptides, and cosmetic and/or pharmaceutical compositions containing such polypeptides are described. The polypeptides have cosmetic and/or therapeutic use to reinforce the barrier function of the epidermis, prevent and/or treat the signs of skin dryness and prevent and/or treat disorders of the barrier function or the weakening of the epidermis.

IPC Classes  ?

• C07K 7/08 - Linear peptides containing only normal peptide links having 12 to 20 amino acids
• A61K 8/64 - ProteinsPeptidesDerivatives or degradation products thereof
• A61Q 19/08 - Anti-ageing preparations
• A61Q 19/00 - Preparations for care of the skin
• C07K 7/06 - Linear peptides containing only normal peptide links having 5 to 11 amino acids
• C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals

Abstract

The present invention relates to a method for producing a substchiometric oxygen layer from titanium, vanadium, tungsten or molybdenum oxide on a substrate by magnetron sputtering a target in a chamber, the method being characterised in that the target consists of titanium, vanadium, tungsten or molybdenum oxide and in that it comprises the steps of: a) creating a vacuum in the chamber and adding an inert gas to same; b) simultaneously applying a first radiofrequency potential to the target and a second radiofrequency potential to the substrate so as to generate, in the chamber, a plasma that is suitable for simultaneously i) sputtering the target to deposit a layer of the titanium, vanadium, tungsten or molybdenum oxide on the substrate; and ii) sputtering the layer of titanium, vanadium, tungsten or molybdenum oxide deposited on the substrate to remove oxygen atoms from the layer.

IPC Classes  ?

• C23C 14/00 - Coating by vacuum evaporation, by sputtering or by ion implantation of the coating forming material
• C23C 14/08 - Oxides
• C23C 14/34 - Sputtering
• C23C 14/35 - Sputtering by application of a magnetic field, e.g. magnetron sputtering
• H01J 37/34 - Gas-filled discharge tubes operating with cathodic sputtering
• H01J 37/32 - Gas-filled discharge tubes
• H01M 4/00 - Electrodes

Abstract

The invention relates to a microfluidic device (1) comprising a frame (32) and two opposite walls (16a,b), the two opposite walls (16a,b) and the frame (32) delimiting together a chamber (2): - the chamber (2) comprising a first zone (4) and a second zone (5), - the second zone (5) comprising a porous member (3) extending in the chamber (2) and comprising a first surface (9) and a second surface (10) opposite to the first surface (9), the first surface (9) separating the chamber (2) in the first zone (4) and in the second zone (5), - the frame (32) comprising at least a first and a second sets of ports (11, 12, 13, 14), the first set of port comprising at least two ports (11, 12) arranged in the frame (32) for fluid circulation within in the first zone (4) and the second set of ports comprising at least two ports (13, 14) arranged in the frame (32) for fluid circulation within the second zone (5), and - the two ports (13, 14) of the second set of ports being open (i) in a microchannel (15) extending through the porous member (3), or (ii) in a cavity (19) arranged between the second surface (10) of the porous member (3) and the frame (32) of the chamber (2). The invention relates to microphysiological systems comprising a microfluidic device and cultured cells on the top surface of the hydrogel matrix. The microphysiological systems may be used to model biological surface or biological tissue at physiological interface comprising a luminal and a stromal compartments, such as colon, pancreas or skin tissue.

IPC Classes  ?

• C12M 3/00 - Tissue, human, animal or plant cell, or virus culture apparatus
• C12M 1/00 - Apparatus for enzymology or microbiology
• C12M 3/06 - Tissue, human, animal or plant cell, or virus culture apparatus with filtration, ultrafiltration, inverse osmosis or dialysis means
• C12M 1/12 - Apparatus for enzymology or microbiology with sterilisation, filtration, or dialysis means

Abstract

A system (1) for generating a signal from a surface (22) having a speed V in a direction U, comprising: a light source (2) emitting a Gaussian beam of light along a first optical path (11); a sensor (3) able to evaluate the effects of the electromagnetic interference of the first beam; an optical splitter (4) located upstream of the sensor (3), generating, from the first beam of light, a second beam of light along a second optical path (12); a focusing lens (5, 6) located on the first and/or the second optical path (11, 12), focusing the beam of light at a distance f and defining an upstream optical path (11′, 12′), and a means (7) for routing the second beam, comprising a mirror redirecting the second path such that the lengths of the first (11′) and second (12′) paths are different.

IPC Classes  ?

• G01B 11/30 - Measuring arrangements characterised by the use of optical techniques for measuring roughness or irregularity of surfaces
• G01B 11/24 - Measuring arrangements characterised by the use of optical techniques for measuring contours or curvatures
• G01B 9/02015 - Interferometers characterised by the beam path configuration
• G01B 9/02 - Interferometers
• G01B 9/02055 - Reduction or prevention of errorsTestingCalibration

Abstract

A system (1) for generating a signal from a surface (22) having a speed V in a direction U, comprising: a light source (2) emitting a Gaussian light beam along a first optical path (11); a sensor (3) able to evaluate the effects of the electromagnetic interference of the first beam; a means (2′, 4) for generating a second Gaussian light beam along a second optical path (12); a second sensor (3′) able to evaluate the effects of electromagnetic interference of the second beam; a focusing lens (5, 6) located on the first and/or the second optical path (11, 12), focusing the light beam at a distance f and defining an upstream optical path (11′, 12′); and a means (4′, 7) for routing the second beam able to redirect the second path (12′) in the direction of the first path (11′).

IPC Classes  ?

• G01B 11/30 - Measuring arrangements characterised by the use of optical techniques for measuring roughness or irregularity of surfaces
• G01B 11/24 - Measuring arrangements characterised by the use of optical techniques for measuring contours or curvatures
• G01B 9/02015 - Interferometers characterised by the beam path configuration
• G01B 9/02 - Interferometers
• G01B 9/02055 - Reduction or prevention of errorsTestingCalibration

Abstract

A method for obtaining the profile of the outer surface (22) of a medium (21) having a median plane (23) comprising the following steps: obtaining two time signals A and B (1002), for, at each instant, a same geometrical target on a readout line of the outer surface (22); determining at least one Doppler frequency (2001) associated with each time signal A and B; sampling each time signal A and B (2002) at a frequency greater than 2 times the Doppler frequency to obtain a payload signal; determining an envelope (2004) of the payload signal of each signal A and B; performing a relative combination between the envelopes of each signal A and B (3001) to obtain a monotonic and bijective function F; and determining the profile of the outer surface (3002) using a calibration of the function F.

IPC Classes  ?

• G01B 11/24 - Measuring arrangements characterised by the use of optical techniques for measuring contours or curvatures

Abstract

The invention relates to a method for producing an environmental barrier coating (12) electrophoretically on a ceramic matrix composite part (10), the method comprising the following steps: - E10: electrophoretic application to the surface (S) of the part (10) of a liquid suspension of a composition comprising at least one rare earth silicate powder and conductive fillers; - E20: drying of the suspension applied; and - E30: sintering heat treatment of the rare earth silicate powder, characterized in that use is made, as conductive fillers, of at least one nitrate selected from the group consisting of aluminium, yttrium and ytterbium nitrates in an amount of between 0.2 and 1 millimole per litre of liquid suspension.

IPC Classes  ?

• C04B 41/45 - Coating or impregnating
• C04B 41/00 - After-treatment of mortars, concrete, artificial stone or ceramicsTreatment of natural stone
• C04B 41/52 - Multiple coating or impregnating
• C04B 41/89 - Coating or impregnating for obtaining at least two superposed coatings having different compositions
• F01D 5/28 - Selecting particular materialsMeasures against erosion or corrosion
• C23C 28/04 - Coating for obtaining at least two superposed coatings either by methods not provided for in a single one of main groups , or by combinations of methods provided for in subclasses and only coatings of inorganic non-metallic material
• C25D 13/02 - Electrophoretic coating characterised by the process with inorganic material
• C25D 13/12 - Electrophoretic coating characterised by the process characterised by the article coated

Abstract

The present invention relates to a device comprising: a) means for measuring the reflectance or absorbance of luminous radiation by an area of the body or an extracorporeal element of an animal within a population of individuals; b) means suitable for receiving luminous-radiation reflectance or absorbance spectral data measured for each animal in the population of individuals; and c) data processing means suitable for determining, according to the received spectral data, a homeostatic emotional state for each animal, the animals being either in an unbalanced homeostatic emotional state or in a balanced homeostatic emotional state.

IPC Classes  ?

• A61B 5/16 - Devices for psychotechnicsTesting reaction times

Abstract

The present invention relates to methods and pharmaceutical compositions for reprograming immune environment in a subject in need thereof. The inventors demonstrated that DDA induces differentiation of tumor cells and stimulates the secretion and the production of modified exosomes with anti-tumor properties (DDA-exosomes) via a mechanism dependent of the expression of the LXRbeta in the parental cells. In particular, one object of the present invention relates to a method of promoting Th1 differentiation and functionality and CD8+ cytotoxicity in a subject in need thereof comprising administering to the subject a therapeutically effective amount of DDA or DDA-exosomes.

IPC Classes  ?

• A61K 31/58 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
• A61P 35/00 - Antineoplastic agents
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 39/39 - Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

The invention relates to a method for forming a cathodic protection coating on a substrate (1) forming a turbomachine part, comprising at least: - the deposition, on the substrate, of particles (11) for the cathodic protection of the substrate, this deposition being effected by electrophoresis from an organic electrolyte (10) comprising at least said particles, and - the formation of an inorganic matrix in a porous area of the particle deposit thus produced, comprising at least: • impregnating said deposit with an impregnating composition, • thermally drying the deposit impregnated with the impregnating composition, and • densifying the deposit by mechanical compaction, after the thermal drying treatment, so as to make said deposit electrically conductive.

IPC Classes  ?

• C25D 13/02 - Electrophoretic coating characterised by the process with inorganic material
• C25D 13/12 - Electrophoretic coating characterised by the process characterised by the article coated
• C23C 18/12 - Chemical coating by decomposition of either liquid compounds or solutions of the coating forming compounds, without leaving reaction products of surface material in the coatingContact plating by thermal decomposition characterised by the deposition of inorganic material other than metallic material
• C25D 13/22 - Servicing or operating
• F01D 5/02 - Blade-carrying members, e.g. rotors

Abstract

The present invention relates to an apheresis column loaded with a solid support comprising a composition comprising at least one peptide selected from the group consisting of: —the αI7I-I85cit peptide of amino acid sequence VDIDIKIX1SCX2GSCS (SEQ ID NO: 8) wherein X1 and X2 each represent a citmllyl residue, —the α62I-635Cit peptide of amino acid sequence X1GHAKSX2PVX3GIHTS (SEQ ID NO: 12) wherein X1, X2 and X3 each represent a citmllyl residue—the P60-74cit-NH2 peptide of amino acid sequence X1PAPPPISGGGYX2AX3 (SEQ ID NO: 15) wherein X1 and X2 each represent a citmllyl residue and X3 represents a citmllyl derivative with a carboxamide group and—the peptide, referred to as the Ac-a36-50crt peptide, having the amino acid sequence GPX1VVEX2HQSACKDS (SEQ ID NO: 6) wherein the residue G at the N-terminal is acetylated and wherein X1 and X2 each represent a citmllyl residue and/or the a36-50cit peptide of amino acid sequence GPX1VVEX2HQSACKDS (SEQ ID NO: 5) wherein X1 and X2 each represent a citmllyl residue.

IPC Classes  ?

• A61M 1/34 - Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration, diafiltration
• A61M 1/36 - Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation

Abstract

The present invention relates to a platelet lysate foam obtained from blood derivative (allogenic or autologous) which retains the biological properties of the platelet lysate and has optimal properties, in particular mechanical but also storage, which allow sale thereof and make handling thereof easier. The present invention relates to a platelet lysate foam obtained from blood derivative (allogenic or autologous) which retains the biological properties of the platelet lysate and has optimal properties, in particular mechanical but also storage, which allow sale thereof and make handling thereof easier. The present invention also relates to the use of a platelet lysate foam for therapeutic purposes, cell culture and cell therapy. The present invention relates to a platelet lysate foam obtained from blood derivative (allogenic or autologous) which retains the biological properties of the platelet lysate and has optimal properties, in particular mechanical but also storage, which allow sale thereof and make handling thereof easier. The present invention also relates to the use of a platelet lysate foam for therapeutic purposes, cell culture and cell therapy. The present invention also relates to a process for getting a platelet lysate foam by a process of drying in a supercritical CO2 atmosphere.

IPC Classes  ?

• A61K 35/19 - PlateletsMegacaryocytes
• A61K 9/12 - AerosolsFoams
• A61K 38/18 - Growth factorsGrowth regulators
• A61K 38/30 - Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
• A61K 33/06 - Aluminium, calcium or magnesiumCompounds thereof
• A61K 31/195 - Carboxylic acids, e.g. valproic acid having an amino group
• A61K 47/42 - ProteinsPolypeptidesDegradation products thereofDerivatives thereof, e.g. albumin, gelatin or zein
• A61L 27/56 - Porous or cellular materials
• A61L 27/36 - Materials for prostheses or for coating prostheses containing ingredients of undetermined constitution or reaction products thereof

Abstract

The present invention relates to methods and pharmaceutical compositions for the treatment of post-operative cognitive dysfunction. In particular, the present invention relates to a method of treating post-operative cognitive dysfunction in a subject in need thereof comprising administering to the subject a therapeutically effective amount of an APJ receptor agonist.

IPC Classes  ?

• A61K 38/22 - Hormones
• A61K 31/015 - Hydrocarbons carbocyclic
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• A61P 23/00 - Anaesthetics
• A61K 31/02 - Halogenated hydrocarbons
• A61K 31/08 - Ethers or acetals acyclic, e.g. paraformaldehyde
• A61K 33/00 - Medicinal preparations containing inorganic active ingredients

Abstract

The present invention relates to sugar-derived catanionic surfactant vesicles comprising anti-inflammatory dendrimers and to their use as a medicament, more particularly in the treatment of psoriasis.

IPC Classes  ?

• A61K 31/80 - Polymers containing hetero atoms not provided for in groups
• A61K 31/66 - Phosphorus compounds
• A61K 47/30 - Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
• A61P 17/06 - Antipsoriatics

Abstract

223166-alkyl group, Ar is selected from the group consisting of aryl and heteroaryl. The compounds of the formula (1) are pharmacologically active compounds. They exhibit high cytotoxicity against cancer cells.

IPC Classes  ?

• C07C 33/02 - Acyclic alcohols with carbon-to-carbon double bonds
• C07D 333/16 - Radicals substituted by singly bound hetero atoms other than halogen by oxygen atoms
• C07D 307/42 - Singly bound oxygen atoms
• A61P 35/00 - Antineoplastic agents
• C07C 33/20 - Monohydroxylic alcohols containing only six-membered aromatic rings as cyclic part monocyclic
• A61K 31/045 - Hydroxy compounds, e.g. alcoholsSalts thereof, e.g. alcoholates
• A61K 31/341 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
• A61K 31/381 - Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings

Abstract

A carbon material comprising particles of hard, non-porous carbon having a spherical morphology, this material having an interlayer distance d002 of more than 3.6 Å and a total specific surface area, measured by the BET N2 method, of less than 75 m2/g, and a method for producing said material. The method further comprises a step of mixing an amine catalyst, an aromatic hydroxyl compound and an aldehyde compound.

IPC Classes  ?

• C01B 32/05 - Preparation or purification of carbon not covered by groups , , ,

Abstract

A process for manufacturing a multi-material part by additive manufacturing, includes the following steps: a) a step of providing a pre-treated metal powder comprising grains and an oxidized and porous layer on a surface of the grains; b) a selective laser powder-bed fusion step comprising implementation of steps i) and ii) as follows: i) a step of forming a layer from the pre-treated metal powder; ii) a step of melting by laser the layer, the melting step being carried out under a reactive atmosphere and comprising changing parameters of application of the laser so that at least a first region of the layer is converted so as to lower the electrical conductivity thereof, thus forming a dielectric, and so that at least a second region of the layer is densified without converting it, the at least a first region being formed when the parameters of application of the laser allow a first energy density to be applied to the first region and/or the laser beam to be kept for a first dwell time on the first region, the at least a second region being formed when the parameters of application of the laser allow a second energy density to be applied to the second region and/or the laser beam to be kept for a second dwell time on the second region, and the first energy density being higher than the second energy density and/or the first dwell time being longer than the second dwell time. A part obtained using the process is also provided.

IPC Classes  ?

• B22F 12/40 - Radiation means
• B22F 10/28 - Powder bed fusion, e.g. selective laser melting [SLM] or electron beam melting [EBM]
• B22F 1/145 - Chemical treatment, e.g. passivation or decarburisation
• B22F 1/16 - Metallic particles coated with a non-metal
• C22C 1/10 - Alloys containing non-metals
• B33Y 10/00 - Processes of additive manufacturing
• B33Y 70/10 - Composites of different types of material, e.g. mixtures of ceramics and polymers or mixtures of metals and biomaterials
• B33Y 40/10 - Pre-treatment

Abstract

The present invention relates to a peptide and its use as a medicament, in particular in the treatment of metabolic syndrome, non-alcoholic fatty liver disease (NAFLD), cardiovascular disease (CVD) or cholestatic liver disease.

IPC Classes  ?

• C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
• A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
• A61K 47/60 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
• C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression
• A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Abstract

The present invention relates to the treatment of idiopathic pulmonary fibrosis. Today, there is no cure for IFF. The inventors showed that EPAC1 inhibitors, in particular CE3F4 and AM-001, represent a promising therapeutic strategy for treating patients with pulmonary fibrosis. The present invention thus relates to an EPAC1 inhibitor for use in the treatment and/or prevention of idiopathic pulmonary fibrosis.

IPC Classes  ?

• A61K 31/4365 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
• A61K 31/47 - QuinolinesIsoquinolines
• A61P 11/00 - Drugs for disorders of the respiratory system

Abstract

A method for removing a component fixed to an aeronautical part, the aeronautical part comprising a first material, and the component comprising a second material different from the first material, the method comprising steps of determining the thicknesses of the component as a function of the position on the component, and of removing the component by means of a pressurized water jet moving over the component as a function of the thicknesses determined in the determination step.

IPC Classes  ?

• F01D 5/28 - Selecting particular materialsMeasures against erosion or corrosion
• B24C 1/04 - Methods for use of abrasive blasting for producing particular effectsUse of auxiliary equipment in connection with such methods for treating only selected parts of a surface, e.g. for carving stone or glass

Abstract

The invention relates to a method for manufacturing an abradable layer and a substrate coated with this layer, comprising the following steps: preparing a powder composition (30) comprising at least ceramic particles and an inorganic filler having a lamellar crystallographic structure, the volume content of the inorganic filler in the powder composition being between 1 and 75%; compressing the powder composition (30); and sintering the powder composition (30) thus compressed in order to obtain the abradable layer (12).

IPC Classes  ?

• C04B 35/447 - Shaped ceramic products characterised by their compositionCeramic compositionsProcessing powders of inorganic compounds preparatory to the manufacturing of ceramic products based on oxides based on phosphates
• C04B 35/486 - Fine ceramics
• C04B 35/488 - Composites
• C04B 35/622 - Forming processesProcessing powders of inorganic compounds preparatory to the manufacturing of ceramic products
• C04B 35/626 - Preparing or treating the powders individually or as batches
• C04B 35/645 - Pressure sintering
• C04B 37/00 - Joining burned ceramic articles with other burned ceramic articles or other articles by heating
• C04B 37/02 - Joining burned ceramic articles with other burned ceramic articles or other articles by heating with metallic articles
• C04B 41/00 - After-treatment of mortars, concrete, artificial stone or ceramicsTreatment of natural stone
• C04B 41/52 - Multiple coating or impregnating
• C04B 41/89 - Coating or impregnating for obtaining at least two superposed coatings having different compositions
• C23C 24/08 - Coating starting from inorganic powder by application of heat or pressure and heat
• C04B 38/00 - Porous mortars, concrete, artificial stone or ceramic warePreparation thereof
• F01D 11/12 - Preventing or minimising internal leakage of working fluid, e.g. between stages for sealing space between rotor blade tips and stator using a rubstrip, e.g. erodible, deformable or resiliently biased part
• C23C 24/04 - Impact or kinetic deposition of particles
• C23C 24/00 - Coating starting from inorganic powder
• C04B 111/00 - Function, property or use of the mortars, concrete or artificial stone

Abstract

The invention relates to a device (10) comprising a first segment (15), a second segment (20), a first contact (25) and a second contact (30), the first segment (15) being made of a semiconductor having a first doping, the second segment (20) being made of a semiconductor having a second doping different from the first, the first segment (15) and the second segment (20) forming a p-n junction comprising a depletion region (70) in the first segment (15), the contacts (25, 30) being configured so that, when a voltage (V1) is applied across the contacts (25, 30), a dimension of the depletion region (70) depends on a value of the voltage, an ionisation energy being defined for dopants of the second segment (20). The device (10) comprises an emitter (40) that generates radiation having an energy higher than the ionisation energy and that irradiates the second segment (20) with the radiation.

IPC Classes  ?

• H01L 25/16 - Assemblies consisting of a plurality of individual semiconductor or other solid-state devices the devices being of types provided for in two or more different subclasses of , , , , or , e.g. forming hybrid circuits
• H01L 33/62 - Arrangements for conducting electric current to or from the semiconductor body, e.g. leadframe, wire-bond or solder balls
• H01L 33/00 - SEMICONDUCTOR DEVICES NOT COVERED BY CLASS - Details thereof
• H01L 33/38 - SEMICONDUCTOR DEVICES NOT COVERED BY CLASS - Details thereof characterised by the electrodes with a particular shape

Abstract

The molecular determinants of chronic pancreatitis leading to pancreatic cancer are underexplored. Genetic or pharmacological inactivation of signaling enzyme PBKa prevents pancreatic fibroinflammatory reaction, while increasing its regenerative capacities, which makes PBKa inhibitors an anti-cancer prevention dmg for these patients. Thus the present invention relates to a method for the prophylactic treatment of cancer in a patient suffering from pancreatitis comprising administering to the patient a therapeutically effective amount of a PBKa- selective inhibitor.

IPC Classes  ?

• A61K 31/553 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and at least one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
• A61P 35/00 - Antineoplastic agents

Abstract

Rapid, easy and early pancreatic cancer diagnosis and therapeutic follow up continue to necessitate an increasing attention towards the development of effective treatment strategies for this lethal disease. The non-invasive quantitative assessment of pancreatic heterogeneity is limited. Here, the inventors report the development of a preclinical imaging protocol using ultrasonography and shear wave technology in an experimental in situ pancreatic cancer model to measure the evolution of pancreatic rigidity. The inventors evaluated the feasiblity of a live imaging protocol by assessing pancreas evolution with Aixplorer technology across 37 weeks. Protumorigenic mutations induced a significant decrease of the rigidity of pancreatic tissue before tumors developed in correlation with the detection of senescent marker p16-positive cells. Thus the promising results indicate the potential of the shear wave elastography to support individualization of diagnosis in this most aggressive disease. Thus, the present invention relates to methods for determining whether a subject has or is at risk of having a pancreatic cancer by using ultrafast elasticity imaging.

IPC Classes  ?

• A61B 8/08 - Clinical applications

Abstract

The invention concerns a binder composition comprising: a. between 1% and 30% in dry weight of Portland cement, lime or a mixture thereof; b. between 1% and 40% in dry weight of ground granulated blast furnace slag; c. between 20% and 50% in dry weight of at least one pozzolanic material; d. between 20% and 65% in dry weight of at least one filler; e. between 0.5% and 10% in dry weight, relative to the total weight of components a, b c and d, of at least one activator; f. between 0.05% and 1.5% in dry weight, relative to the total weight of components a, b, c and d, of at least one water reducer polymer; said filler being a particles mixture of: - between 10% and 90% in weight, in respect with the total weight of the filler, of particles having a d50 greater than or equal to 0,05?m and strictly less than 8?m, and - between 10% and 90% in weight, in respect with the total weight of the filler, of particles having a d50 greater than or equal to 8?m and strictly less than 200?m.

IPC Classes  ?

• C04B 28/04 - Portland cements
• C04B 28/12 - Hydraulic lime

Abstract

The above objectives are reached thanks to a binder composition comprising: a. between 1% and 30% in dry weight of at least one lime source; b. between 5% and 75% in dry weight of ground granulated blast furnace slag; c. between 20% and 90% in dry weight of at least one filler; d. between 0.1% and 5% in dry weight, relative to the total weight of components a, b and c, of SO3-; e. between 0.1% and 1% in dry weight, relative to the total weight of components a, b and c, of at least one water reducer polymer; f. between 0% and 2% in dry weight, relative to the total weight of components a, b and c, of at least one activator different from d.; said ground granulated blast furnace slag being a particles mixture of : - between 10% and 100% in weight, in respect with the total weight of the ground granulated blast furnace slag, of particles having a d50 greater than or equal to 1µm and strictly less than 5µm, - between 0% and 90% in weight, in respect with the total weight of the ground granulated blast furnace slag, of particles having a d50 greater than or equal to 5µm and preferably less than 15µm, said filler being a particles mixture of : - between 10% and 90% in weight, in respect with the total weight of the filler, of particles having a d50 greater than or equal to 0,05µm and strictly less than 8µm, and - between 10% and 90% in weight, in respect with the total weight of the filler, of particles having a d50 greater than or equal to 8µm and strictly less than 200µm.

IPC Classes  ?

• C04B 28/08 - Slag cements
• C04B 40/06 - Inhibiting the setting, e.g. mortars of the deferred action type containing water in breakable containers

Abstract

505050 greater than or equal to 8μm and strictly less than 200μm.

IPC Classes  ?

• C04B 28/04 - Portland cements
• C04B 28/12 - Hydraulic lime
• C04B 111/60 - Flooring materials

Abstract

350505050 greater than or equal to 0,05µm and strictly less than 8µm, and - between 10% and 90% in weight, in respect with the total weight of the filler, of particles having a d50 greater than or equal to 8µm and strictly less than 200µm.

IPC Classes  ?

• C04B 28/08 - Slag cements
• C04B 40/06 - Inhibiting the setting, e.g. mortars of the deferred action type containing water in breakable containers

Abstract

The present invention relates to a method for selecting at least one micropeptide able to alter the microbiome influenced by roots of a plant based on identifying miRNAs secreted by said plant in a sample of the roots and/or rhizosphere. The present invention also relates to a micropeptide able to alter the microbiome influenced by roots of a plant and its use as a plant microbiome modulating agent, for example for inducing a phenotype of interest, such as a pathogen resistance and/or a water resistance.

IPC Classes  ?

• A01H 1/00 - Processes for modifying genotypes
• A01H 3/04 - Processes for modifying phenotypes by treatment with chemicals
• C07K 7/08 - Linear peptides containing only normal peptide links having 12 to 20 amino acids
• A01N 33/00 - Biocides, pest repellants or attractants, or plant growth regulators containing organic nitrogen compounds

Abstract

The invention is based on the discovery of a new bacterial compound with analgesic properties which could be used as a new tool for the treatment of pain disorders such as visceral pain. Studying the mechanisms implicated in analgesic properties of the probiotic Escherichia coli strain Nissle 1917 (EcN), inventors characterized, the amino fatty acids produced by EcN, which display the Ecn analgesic properties. One of these compounds inhibits the hypersensitivity to colorectal distension induced by capsaicin, which is a very powerful nociceptive compound and acts via the GABA B receptor. Furthermore, inventors demonstrate that this compound is able to cross the cellular epithelial barrier (such as the intestinal epithelium). Thus, the invention relates to a lipopeptide compound, derived from gamma-aminobutyric acid. The invention also relates to a lipopeptide compound according to the invention for the treatment of treating pain disorder, such as somatic pain and visceral pain.

IPC Classes  ?

• A61K 31/197 - Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]

Abstract

The present invention relates to a culture medium and a culture method for obtaining, in a single step and in the same culture container, cells differentiated into osteoblasts and adipocytes as well as a network of organized endothelial cells from the same pool of mesenchymal stem cells and/or a mixture of mesenchymal stem cells, endothelial progenitor cells, and endothelial cells, selected beforehand and amplified simultaneously in the same culture container from a single sample. The invention also relates to a composition obtained by said method, to a bone marrow reconstitution, and to uses thereof.

IPC Classes  ?

• C12N 5/0775 - Mesenchymal stem cellsAdipose-tissue derived stem cells
• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues
• C12N 5/077 - Mesenchymal cells, e.g. bone cells, cartilage cells, marrow stromal cells, fat cells or muscle cells

Abstract

A method for coating a turbomachine part includes depositing a paint by electrophoresis on the part, a voltage between the part and a counter electrode being controlled during the deposition by imposing a sequence of pulsed voltage cycles, each cycle having: (i) a first voltage stabilization phase during which a first potential difference is imposed between the part and the counter electrode, and a second voltage stabilization phase during which a second potential difference is imposed, an absolute value of the first potential difference being between 0.1 V and 30 V, and an absolute value of the second potential difference being less than the absolute value of the first potential difference, the second potential difference being not equal to zero or being equal to zero, and (ii) a ratio R [duration of the first phase]/[duration of the first phase+duration of the second phase] between 1:10 and 1:3.

IPC Classes  ?

• C25D 13/18 - Electrophoretic coating characterised by the process using modulated, pulsed or reversing current
• C25D 13/02 - Electrophoretic coating characterised by the process with inorganic material
• C25D 13/12 - Electrophoretic coating characterised by the process characterised by the article coated

Abstract

Escherichia coli strain Nissle 1917 (EcN) bacterium carrying a gene encoding ClbP protein which is inactive for the peptidase domain, and its use as a drug and more particularly for use in the treatment of gastro-intestinal disease.

IPC Classes  ?

• A61K 35/741 - Probiotics
• A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system
• C12N 1/20 - BacteriaCulture media therefor
• C12N 9/48 - Hydrolases (3.) acting on peptide bonds, e.g. thromboplastin, leucine aminopeptidase (3.4)
• C12R 1/19 - Escherichia coli

Abstract

The present invention relates to a method and a unit for preparing a solid material for storing ozone, said method comprising contacting cyclodextrins and/or derivatives of cyclodextrins in solid form with a gas comprising ozone, by means of which a solid material for storing ozone is obtained. The present invention also relates to the material thus prepared and to the uses thereof.

IPC Classes  ?

• C01B 13/10 - Preparation of ozone
• B01J 20/24 - Naturally occurring macromolecular compounds, e.g. humic acids or their derivatives
• A61L 9/04 - Disinfection, sterilisation or deodorisation of air using gaseous or vaporous substances, e.g. ozone using substances evaporated in the air without heating
• A61L 2/20 - Gaseous substances, e.g. vapours
• A01N 25/10 - Macromolecular compounds
• A01N 59/00 - Biocides, pest repellants or attractants, or plant growth regulators containing elements or inorganic compounds
• A01P 1/00 - DisinfectantsAntimicrobial compounds or mixtures thereof
• A61K 33/00 - Medicinal preparations containing inorganic active ingredients
• A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
• C02F 1/78 - Treatment of water, waste water, or sewage by oxidation with ozone
• C02F 1/50 - Treatment of water, waste water, or sewage by addition or application of a germicide or by oligodynamic treatment

Abstract

The present invention provides cationic peptoid / N-substituted peptidic copolymers, and pharmaceutical compositions thereof, as described generally and in subclasses herein, which compounds are useful for the treatment of microbial infections.

IPC Classes  ?

• C07K 14/00 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
• A61K 47/00 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient
• A61P 31/04 - Antibacterial agents
• A61K 38/00 - Medicinal preparations containing peptides
• A61L 27/00 - Materials for prostheses or for coating prostheses

Abstract

This rack is configured for analyzing the behavior and the physical activity of a population of animals (M1-M4) housed in cages (14) distributed in respective cells (8, 8k), at least some of the cages being equipped with an exercise wheel (20). At least a first cell (82, 83) is provided with a proximity sensor (30) configured for detecting a tag (Ti) carried by an animal located in the exercise wheel (20) of a first cage installed within the first cell, this cage being devoid of a proximity sensor.

IPC Classes  ?

• A01K 1/03 - Housing for domestic or laboratory animals
• A01K 11/00 - Marking of animals
• A01K 15/02 - Training or exercising equipment, e.g. mazes or labyrinths for animals
• A01K 29/00 - Other apparatus for animal husbandry
• G06K 7/10 - Methods or arrangements for sensing record carriers by electromagnetic radiation, e.g. optical sensingMethods or arrangements for sensing record carriers by corpuscular radiation
• H01Q 17/00 - Devices for absorbing waves radiated from an antenna Combinations of such devices with active antenna elements or systems

Abstract

The present invention relates to compounds of formula (I), which are artemisinin-derivative N-heterocyclic carbene gold (1) hybrid complexes, and to their therapeutic uses.

IPC Classes  ?

• C07F 1/00 - Compounds containing elements of Groups 1 or 11 of the Periodic Table
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61K 31/28 - Compounds containing heavy metals
• A61P 35/00 - Antineoplastic agents

Abstract

The present invention relates to the treatment of type 2 inflammation or mast-cell dependent disease. The inventors showed that, when exposed to domestic allergic alarms, activation of TRPV1+Tac1+ nociceptor-MRGPRB2+ MC sensory clusters might represent a key early event controlling the development of frequent mast cell-dependent allergic disorders. The human ortholog of MRGPRB2 (MRGPRX2) can thus be a good target to treat type 2 inflammation or mast cell-dependent disorders. Thus, the present relates to a MRGPRX2 inhibitor for use in the treatment of a type 2 inflammation or mast cell-dependent disorders in a subject in need thereof.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61P 37/08 - Antiallergic agents

Abstract

2/g, involves: —choosing a phyllosilicate composition, including mineral particles having a thickness of less than 100 nm, a largest dimension of less than 10 μm and belonging to the family of lamellar silicates; —choosing at least one functionalizing agent, from the group formed from the oxysilanes and oxygermanes having at least one organic group, —bringing the phyllosilicate composition into contact with a functionalizing solution including the functionalizing agent, so as to obtain a phyllosilicate composition including mineral particles functionalized by the organic group, while choosing the organic group from the group formed from the cationic heteroaryl groups, the quaternary ammonium groups and the salts of same. The phyllosilicate composition obtained by the method is also described.

IPC Classes  ?

• C09C 1/30 - Silicic acid
• C01B 33/44 - Products obtained from layered base-exchange silicates by ion-exchange with organic compounds such as ammonium, phosphonium or sulfonium compounds or by intercalation of organic compounds, e.g. organoclay material
• C09C 1/00 - Treatment of specific inorganic materials other than fibrous fillers Preparation of carbon black

Abstract

The present invention relates to methods of enhancing the potency of incretin-based drugs in subjects in need thereof. Through different animal models, the inventors identified that a specific gut microbiota signature impairs GLP-1-activated gut-brain axis which could be transferred to germ free mice. The dysbiotic gut microbiota induces enteric neuropathy, reduces GLP-1 receptor and nNOS mRNA concentration, GLP-1-induced nitric oxide production for the control of insulin secretion and gastric emptying. The frequency of Lactobacilli in the ileum microbiota was tightly correlated with nMOS mRNA concentration, which is a mode of action of GLP-1, of the enteric nervous system opening a novel route for the improvement of GLP-1 based therapies in type 2 diabetic patients. In particular, the present invention relates to a method of enhancing the potency of an incretin-based drug administered to a diabetic subject as part of a treatment regimen.

IPC Classes  ?

• A61K 35/747 - Lactobacilli, e.g. L. acidophilus or L. brevis
• A23L 33/135 - Bacteria or derivatives thereof, e.g. probiotics
• A61P 5/48 - Drugs for disorders of the endocrine system of the pancreatic hormones
• A61P 3/08 - Drugs for disorders of the metabolism for glucose homeostasis
• A61P 3/04 - AnorexiantsAntiobesity agents
• A61K 9/00 - Medicinal preparations characterised by special physical form

Abstract

Active forms of specific anti Rho GTPase conformational single domain antibodies are useful in the therapeutic and diagnostic fields. In particular, single domain antibodies wherein the amino acid sequences of CDR1-IMGT, CDR2-IMGT and CDR3-IMGT have at least 90% of identity with the amino acid sequences of the CDR1-IMGT, CDR2-IMGT and CDR3-IMGT of the H12, B6, 4P75, 4SP1, 4SNP36, 4SNP61, 5SP10, 5SP11, 5SP58, 5SNP47, 5SNP48, 5SNP65, B20, B15, B5, B71, E3, A6, G12, NB61, 212B, 111B or 404F (hs2dAb) are defined in Table B.

IPC Classes  ?

• C07K 16/40 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against enzymes
• C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells

Abstract

] The present invention relates to the field of cancer diagnostic methods for classifying cancer patients using a measure of the distribution of markers of DNA structure alterations within tumor genomic DNA sequence. The inventors have observed, in sarcomas, such as leiomyosarcoma, that the distribution of breakpoints within a set of selected transcription-associated chromosomal instability elements and a set of selected replication-associated chromosomal instability elements can be used to classify patients in groups according to a level of genome instability, which may be representative of a cancer evolution, a risk of occurrence of metastasis, a survival rate, or a sensibility to a cancer treatment. The present invention also relates to machine learning and trained classifiers for classifying patients having a cancer based upon a distribution of genomic DNA structure alterations or variations.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
• G16B 20/20 - Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
• G16B 40/00 - ICT specially adapted for biostatisticsICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
• G16B 40/20 - Supervised data analysis
• G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment

Abstract

Immune checkpoint blockade therapy is based on the inhibition of the tumor-mediated suppression of anticancer immune responses. However, the efficacy and effectiveness of said therapy vary greatly across individual patients and among different tumor types. A substantial unmet need is thus to identify novel targets that can enhance the therapeutic efficacy of the immune checkpoint blockade therapy. S1P is produced by sphingosine kinases (i.e. SK1 and SK2) that catalyze the phosphorylation of sphingosine to SIP. SK2 inhibitors were described as suitable for the treatment of cancer. However the role of SK2 in the immune tumor microenvironment has never been investigated. The inventors now showed that genetic deletion of SPHK2 leads to a delay in the melanoma tumor growth and an increase in tumor-infiltrating effector lymphocytes. In particular the increase of tumor-infiltrating effector lymphocytes in the tumor is associated with a decrease in the amount of tumor-infiltrating myeloid-derived suppressor cells. Moreover, the combination of SPHK2 deficiency with immune-checkpoint blockade leads to tumor rejection and increases survival rate. Accordingly, the present invention relates to use of SK2 inhibitors in combination with immune checkpoint blockade therapy for the treatment of cancer.

IPC Classes  ?

• A61K 31/4409 - Non-condensed pyridinesHydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61P 35/00 - Antineoplastic agents

Abstract

The present invention relates to a complex of cationic or neutral gold (I) with fluorinated NHC ligands, as well as the uses thereof as an anti-oxidant, anti-cancer, anti-bacterial and/or anti-parasitic agent and, in particular, an anti-leishmanial agent.

IPC Classes  ?

• C07F 1/00 - Compounds containing elements of Groups 1 or 11 of the Periodic Table
• A61P 35/00 - Antineoplastic agents
• C07H 23/00 - Compounds containing boron, silicon or a metal, e.g. chelates or vitamin B12

Abstract

The invention relates to a method for detecting cell death using PCR (polymerase chain reaction) techniques, including qPCR/quantitative PCR or ddPCR/digital droplet PCR, or any other technique for detecting a small amount of DNA (such as nanostrings).

IPC Classes  ?

• C12Q 1/6806 - Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
• C12Q 1/686 - Polymerase chain reaction [PCR]
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing

Abstract

The present invention belongs the field of ecotoxicology and more specifically to measuring the ecotoxic potential of an aqueous effluent. The subject matter of the present invention relates to a method for measuring the ecotoxic potential of an aqueous effluent and to a device for implementing the method, the device comprising an array of instrumented and transportable mesocosms. The invention also relates to the use of the device for measuring the ecotoxic potential of an effluent and to a kit of instrumented and transportable mesocosms.

IPC Classes  ?

• G01N 33/18 - Water

Abstract

Rheumatoid arthritis (RA) is the most prevalent chronic autoimmune inflammatory rheumatism. Its pathophysiology is largely dependent on TNF. Severe RA as well as several other inflammatory and autoimmune diseases are treated with TNF inhibitors (TNFi). However, to date only 30-50% achieve low disease activity or remission with this treatment regimen and some patients experience secondary non-response or relapse. Herein, the inventors evaluated by RT-qPCR the mRNA expression of CD36, which was already described to be regulated by TNFi5, some specific NRF2 target genes (FBX030, GABARA, LBR, MAFG, OSGIN1, HMOX1), which play a role in the anti-oxidative stress response or anti-inflammatory pathway, and the expression of CSMD1, an anti-inflammatory gene that we observed as up-regulated by all TNFi. Interestingly, they observed 2 different subsets of healthy donors: (i) donors in which TNFi stimulation increased mRNA of target genes in macrophages and (ii) conversely donors with no significant upregulation in transcription of these target genes. Then they classified donors two different status, "activators" or "non-activators" of tmTNF reverse signaling after TNFi stimulation, which correlates to clinically responder and non-responders to TNFi. Thus, based on all these observations, they developed an in vitro method for predicting the response to TNF inhibitors in patient in need thereof.

IPC Classes  ?

• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material

Abstract

Resistance of acute myeloid leukemia (AML) cells to DNA damaging therapeutic agents is dependent on CHK1 protein levels. Here, the inventors demonstrate that in AML, CHK1 protein stability relies on the expression and activity of Ubiquitin Specific Protease 7 (USP7). CHK1 and USP7 levels are positively correlated in AML cell lines and primary patient specimens with high CHK1 protein levels. USP7 associates with CHK1, leading to its stabilization by deubiquitinylation, and this association is enhanced in response to cytarabine treatment. Pharmacological or RNA interference-mediated inhibition of USP7 significantly reduced AML proliferation in vitro and in vivo, and increased AML cell death. It is important to note that USP7 inhibition synergized with cytarabine to kill AML cell lines. This is also the case in primary patient specimens with high CHK1 levels. Transcriptomic dataset analyses revealed that a USP7 gene signature is highly enriched in cells from AML patients at relapse, as well as in residual blasts from Patient Derived Xenograft (PDX) models treated with clinically relevant doses of cytarabine, strongly suggesting a relationship between USP7 expression and resistance to therapy. Finally, single cell analysis from AML patient at relapse versus diagnosis showed that a gene signature of the pre-existing subpopulation responsible for relapse is enriched in transcriptomes of patients with high USP7 level. Altogether, these data demonstrate that USP7 is a master regulator of CHK1 protein kinase in AML cells, and represents both a marker of resistance to chemotherapeutic treatments, as well as a potential therapeutic target to overcome treatment resistance.

IPC Classes  ?

• A61K 31/381 - Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
• A61P 35/02 - Antineoplastic agents specific for leukemia
• A61K 31/7068 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid

Abstract

The invention relates to a method for impregnating a roving made of oxide fibres (11) with an alumina and silica matrix, comprising a step (4) of introducing an oxide fibre roving into an impregnation bath (15), characterised in that the impregnation bath is produced by the sol-gel route and comprises a silica precursor in the form of a hybrid polymeric sol, and an alumina precursor in the form of a colloidal sol and ceramic particles.

IPC Classes  ?

• C04B 35/117 - Composites
• C04B 35/14 - Shaped ceramic products characterised by their compositionCeramic compositionsProcessing powders of inorganic compounds preparatory to the manufacturing of ceramic products based on oxides based on silica
• C04B 35/18 - Shaped ceramic products characterised by their compositionCeramic compositionsProcessing powders of inorganic compounds preparatory to the manufacturing of ceramic products based on oxides based on silicates other than clay rich in aluminium oxide
• C04B 35/624 - Sol-gel processing
• C04B 35/628 - Coating the powders
• C04B 35/634 - Polymers
• C04B 35/80 - Fibres, filaments, whiskers, platelets, or the like
• D02J 3/00 - Modifying the surface
• D06M 11/00 - Treating fibres, threads, yarns, fabrics or fibrous goods made from such materials, with inorganic substances or complexes thereofSuch treatment combined with mechanical treatment, e.g. mercerising
• D06B 3/10 - Passing of textile materials through liquids, gases, or vapours to effect treatment, e.g. washing, dyeing, bleaching, sizing, impregnating of fabrics
• D06C 9/00 - Singeing

Abstract

The invention relates to the domain of anemia, iron overload and myeloid malignancy. The inventors identify a variant transcript of ERFE specific of SF3B1MUT MDS that contributes to increased concentration of ERFE protein leading to hepcidin suppression and iron accumulation in patients. This transcript contains an in-frame added intronic sequence of 12 nucleotides not inducing a stop codon that may be translated into a variant protein with an additional 4 amino acids. By using deep mass spectrometry, they identified a peptide corresponding to the added polypeptide VPQF (SEQ ID NO: 5) demonstrating the active production of a variant protein by bone marrow erythroblasts of patients with a SF3B1-mutated MDS. This variant can be used as a pertinent biomarker of clonal erythropoiesis for monitoring treatments of anemia in SF3B1MUT patients. Thus, the invention relates to a variant of the transcript of ERFE and its use in diagnosing and monitoring of anemia and iron overload in patient with a myeloid malignancy with at least one mutation in the SF3B1 gene.

IPC Classes  ?

• C07K 16/26 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones
• C07K 14/575 - Hormones
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• A61P 7/06 - Antianaemics
• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material

Abstract

The present invention relates to (poly)peptides comprising a sequence consisting of a LC3-interacting region (LIR) core motif and specific linker peptidic sequences. These (poly)peptides selectively bind, with high affinity, protein(s) of the ATG8 family, and can advantageously be used for the capture and/or the detection of protein(s) of the ATG8 family, as well as the identification of autophagy inhibitors.

IPC Classes  ?

• C07K 7/00 - Peptides having 5 to 20 amino acids in a fully defined sequenceDerivatives thereof
• C07K 14/00 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
• G01N 33/557 - ImmunoassayBiospecific binding assayMaterials therefor using kinetic measurement, i.e. time rate of progress of an antigen-antibody interaction
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
• C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing

Abstract

Methods for making a synthetic mineral and methods for making synthetic mineral precursors and the products of said methods.

IPC Classes  ?

• C01B 33/22 - Magnesium silicates
• C01G 17/00 - Compounds of germanium

Abstract

Anthracyclines such as doxorubicin are chemotherapeutic molecules are also widely incorporated in many chemotherapy protocols. However, their clinical use is still limited by time- and dose-dependent cardiotoxicity. Herein the inventors have determined the therapeutic potential of acidic nanoparticles (NPs) in doxo-treated cardiac cells. In particular, they have identified a set of grafted nanoparticles as non-toxic and which rapidly internalize into lysosomes in cardiac cells. Such NPs improve lysosomal acidification and autophagic flux blockade caused by bafilomycin A1, chloroquine and doxorubicin, resulting in reduced oxidative stress, preserved mitochondrial integrity and improved cell survival. Thus, the invention relates to a biocompatible and biodegradable nanoparticle having a diameter of 100 nm or less, wherein the nanoparticle is selected from: a poly(lactic-co-glycolic acid) (PLGA) nanoparticle, a poly(lactic acid) (PLA) nanoparticle, a poly(glutamic acid) (PGA) nanoparticle, a polycaprolactone (PCL) nanoparticle, and/or a polyester nanoparticle; for use in a method for treating or preventing a cardiomyopathy or anthracycline cytotoxicity.

IPC Classes  ?

• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/16 - AgglomeratesGranulatesMicrobeadlets
• A61K 9/51 - Nanocapsules
• A61K 31/704 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin, digitoxin
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

A method for producing a permanent or soft magnet including the following steps: a) providing: a solution containing a solvent in which are dispersed a set of objects which possess a permanent magnetic moment; a substrate on which are fixed to the surface or within a cavity that it may have, a 1st pad and a 2nd pad, said 1st pad includes a face facing and parallel to a face that the 2nd pad includes; b) the solution is deposited on the surface of the substrate or, as the case may be, within its cavity; c) the substrate is placed in a magnetic field so that the set of objects are grouped together between the face of the 1st pad and the face of the 2nd pad so as to form a permanent magnet.

IPC Classes  ?

• H01F 7/02 - Permanent magnets
• H01F 1/053 - Alloys characterised by their composition containing rare earth metals
• H01F 1/055 - Alloys characterised by their composition containing rare earth metals and magnetic transition metals, e.g. SmCo5
• H01F 1/08 - Magnets or magnetic bodies characterised by the magnetic materials thereforSelection of materials for their magnetic properties of inorganic materials characterised by their coercivity of hard-magnetic materials metals or alloys in the form of particles, e.g. powder pressed, sintered, or bound together

Abstract

molding by compression the face of the substrate (12) with a face of a reference element (22) having a surface roughness less than or equal to 50 nanometers.

IPC Classes  ?

• B29C 43/24 - Calendering
• B29C 43/02 - Compression moulding, i.e. applying external pressure to flow the moulding materialApparatus therefor of articles of definite length, i.e. discrete articles
• B29C 59/00 - Surface shaping, e.g. embossingApparatus therefor
• B29C 59/02 - Surface shaping, e.g. embossingApparatus therefor by mechanical means, e.g. pressing
• H10K 77/10 - Substrates, e.g. flexible substrates
• B29L 31/34 - Electrical apparatus, e.g. sparking plugs or parts thereof
• H10K 71/00 - Manufacture or treatment specially adapted for the organic devices covered by this subclass

Abstract

Bilateral congenital anomalies of the kidney and urinary tract (CAKUT) are the main cause of childhood chronic kidney disease (CKD). Accurate and non-biased prenatal prediction of postnatal disease evolution is currently lacking, but is essential for prenatal counseling and disease management. Here the inventors aimed to develop an objective and quantifiable risk prediction method based on amniotic fluid (AF) peptides. 178 fetuses with bilateral CAKUT were included in a prospective multicenter study. The AF peptide content was studied using capillary electrophoresis coupled to mass spectrometry. The endpoint was early-onset renal failure (CKD stage 3-5) or death due to end-stage renal disease at two years of age. Among the ˜7000 peptide candidates, 98 were associated with early severe renal failure. The most frequently found peptides associated with severe disease were fragments from extracellular matrix proteins and thymosin-P4. Combination of those 98 peptides in a classifier lead to the prediction of postnatal renal outcome in a blinded validation set of 51 patients with a 88% (95% CI: 64-98) sensitivity, 97% (95% CI: 85-100) specificity and an AUC of 0.96 (95% CI: 0.87-1.00), outperforming predictions based on currently used clinical methods. The classifier also predicted normal postnatal renal function in 75% of terminated pregnancies where fetopathology showed kidneys compatible with normal life. Analysis of AF peptides thus allows a precise and quantifiable prediction of postnatal renal function in bilateral CAKUT with potential major impact on pre- and postnatal disease management.

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
• G16B 40/20 - Supervised data analysis

Abstract

The mechanisms of tumor escape are numerous, but the immunosuppressive action of coinhibitory molecules has emerged this last decade as the most attractive one for imaging new treatments of cancer. Activation of lymphocytes is indeed regulated by both costimulatory and coinhibitory molecules also called “immune checkpoints”. Now the inventors show that T cell activation triggers mRNA and protein expression of stress granule components and more particularly show that immune checkpoint mRNA interact with said stress granules. More importantly, stress granule inhibitors impair expression of immune checkpoint and thus represent an attractive target for targeting the regulation of immune response.

IPC Classes  ?

• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

The present invention relates to a TLR4 (toll-like receptor 4) specific antagonist for use in the treatment of multiple myeloma in a subject suffering from multiple myeloma, and also to an antitumor pharmaceutical combination comprising (i) a TLR4-specific antagonist and (ii) a chemotherapy agent for simultaneous, separate or sequential use in the treatment of multiple myeloma.

IPC Classes  ?

• A61K 31/7008 - Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
• A61P 35/00 - Antineoplastic agents

Abstract

After intensive chemotherapy, the emergence of cells with dmg resistant and/or stem cell features might explain frequent relapses and the poor outcome of patients with acute myeloid leukemia (AML). Herein the inventors first uncovered that the adrenomedullin receptor CALCRL is overexpressed in AML patients comparing with normal cells and preferentially in the immature CD34+ CD38− compartment. Then they demonstrated its role in the maintenance of leukemic stem cell function in vivo. Moreover, CALCRL depletion strongly affected leukemic growth in xenograft models and sensitized to chemotherapeutic agent cytarabine in vivo. It Accordingly, the inventors showed that ADM-CALCRL axis drove cell cycle, DNA integrity, and high OxPHOS status of chemoresistant AML stem cells in an E2F1- and BCL2-dependent manner. Furthermore, CALCRL depletion sensitizes cells to cytarabine and its CT expression predicted the response to chemotherapy in vivo in mice. Further, using the combination of limiting dilution assays, single-cell RNA-seq analysis of primary AMF samples at diagnosis and relapse and before and after transplantation in NSG mice, the inventors revealed the pre-existence of a chemoresistant leukemic stem cell sub-population harboring a CALCRL-driven gene signature. Finally the inventors strongly demonstrated that chemoresistant LSC are dependent for CALCRL. All of these data highlight the critical role of CALCRL in stem cell survival, proliferation and metabolism and identify this receptor as a new marker of chemoresistant leukemic stem cell population and a promising therapeutic target to specifically eradicate them and overcome relapse in AML.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61P 35/02 - Antineoplastic agents specific for leukemia
• A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer

Abstract

The present invention relates to a method and a unit for preparing a solid material for storing ozone, said method comprising contacting carbohydrates and/or derivatives of carbohydrates in solid form with a gas comprising ozone, by means of which a solid material for storing ozone is obtained. The present invention also relates to the material thus prepared and to the uses thereof.

IPC Classes  ?

• C01B 13/10 - Preparation of ozone
• B01J 20/24 - Naturally occurring macromolecular compounds, e.g. humic acids or their derivatives
• A61L 2/20 - Gaseous substances, e.g. vapours
• C02F 1/28 - Treatment of water, waste water, or sewage by sorption
• C02F 1/78 - Treatment of water, waste water, or sewage by oxidation with ozone
• C08L 1/28 - Alkyl ethers
• C08L 1/00 - Compositions of cellulose, modified cellulose, or cellulose derivatives
• C08L 3/00 - Compositions of starch, amylose or amylopectin or of their derivatives or degradation products
• C08L 5/00 - Compositions of polysaccharides or of their derivatives not provided for in group or

Abstract

To overcome the difficulty in achieving a quantitative assessment of CTL function in clinical settings, the inventors aimed at developing a new method inspired by their knowledge of the CTL/tumor target biology and based on flow cytometry. In particular, to directly detect the earliest steps of tumor cell resistance to CTL attack at the lytic synapse the inventors developed a method to monitor CTL/tumor cells interaction in the presence of FM1-43, a fluorescent lipophilic dye that rapidly intercalates into lipid bilayer during the membrane turnover that accompanies plasma membrane reparation. This assay allows the inventors to measure reparative membrane turnover of tumor cells under CTL attack by FACS analysis at the whole tumor cell population level. They initially applied this approach to compare the response of melanoma cell (D10 cells) to CTL attack as compared to conventional target cells that are sensitive to CTL mediated cytotoxicity (EB V-transformed B cells, JY cells). The methodology allows to rapidly assessing the synaptic resistance of tumor target cells to CTL attack and the intrinsic capacity of CD8+CTL to efficiently kill their target cells. Thus, the present invention relates to methods and kit for assaying lytic potential of immune effector cells and uses thereof in diagnostic assays.

IPC Classes  ?

• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing

Abstract

The present invention relates to the treatment of T-helper type 2 (Th2)-mediated disease. Here, the inventors set out to investigate at the genome level the effects of SETDB1-dependent H3K9me3 deposition on CD4 T cell activation, differentiation and commitment. By using conditional Setdb1−/− mice, they show that SETDB1 restricts Th1 cell priming and ensures Th2 cell integrity. Unlike their wild-type counterparts, SETDB1-deficient Th2 cells readily express the entire Th1 gene network when exposed to the Th1-instructing cytokine IL-12. More, SETDB1 methylates H3K9 at a subset of ERVs that flank and repress Th1 enhancers or behave themselves as cis-regulatory elements of a large network of Th1 genes, including Ifng, Stat4, Runx3 and Tbx21. Therefore, H3K9me3 deposition by SETDB1 locks the Th1 gene expression program and thus ensures T cell lineage integrity by repressing a repertoire of ERVs that have been co-opted to behave as Th1 lineage-specific cis-regulatory modules. Thus, the invention relates to a SETDB1 inhibitor for use in a method for increasing the Th1/Th2 ratio of an immune response in a subject in need thereof.

IPC Classes  ?

• A61K 31/704 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin, digitoxin
• A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
• A61K 31/337 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
• A61K 39/39 - Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
• A61P 37/08 - Antiallergic agents

Abstract

Despite reaching an epidemic status worldwide, metabolic disorders, notably diabetes, still miss efficient and specific therapeutic strategies because of their multifactorial origin. SHP2 is a ubiquitous tyrosine phosphatase that regulates major signalling pathways (e.g. MAPK, PI3K) in response to many growth factors. The inventors evaluate whether chronic inhibition of SHP2 could improve insulin sensitivity in animal models. Obese diabetic mice were thus treated by gavage (50 mg/kg/day). And the inventors note a significant improvement in the glucose tolerance of the treated animals compared to their control, with a decreased fasting blood glucose, without any change in weight or body composition. Accordingly, the present invention relates to use of SHP2 inhibitors for the treatment of insulin resistance.

IPC Classes  ?

• A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Abstract

The invention relates to the identification of a highly stable single domain antibody scaffold (hs2dAb) and its use in generating synthetic single domain antibody library (hs2dAb-L1). The invention also relates to antigen-binding proteins comprising said stable single domain antibody scaffold and their uses, in particular as therapeutics.

IPC Classes  ?

• C40B 50/06 - Biochemical methods, e.g. using enzymes or whole viable microorganisms
• C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies
• C07K 16/32 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products from oncogenes
• C07K 16/44 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere
• C40B 40/08 - Libraries containing RNA or DNA which encodes proteins, e.g. gene libraries
• C07K 16/40 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against enzymes
• C40B 40/10 - Libraries containing peptides or polypeptides, or derivatives thereof

Abstract

Disclosed is a system for generating a signal of a surface (22) having a velocity V In a direction U, the system comprising: - a light source (2) emitting a Gaussian beam of light along a first optical path (11); - a sensor (3) capable of evaluating the effects of the electromagnetic interference of the first beam; - a beam splitter (4), located upstream of the sensor (3), generating from the first light beam a second light beam along a second optical path (12); - a focusing lens (5, 6), located on at the first optical path and/or the second optical path (11, 12), focusing the light beam at a distance f and defining an optical path (11', 12') upstream; and - a means for routing (7) the second beam, comprising a mirror redirecting the second path so that the lengths of the first (11') and second (12') paths are different.

IPC Classes  ?

• G01B 9/02 - Interferometers
• G01B 11/24 - Measuring arrangements characterised by the use of optical techniques for measuring contours or curvatures
• G01B 11/30 - Measuring arrangements characterised by the use of optical techniques for measuring roughness or irregularity of surfaces

Abstract

Disclosed is a system for generating a signal of a surface (22) having a velocity V In a direction U, the system comprising: - a light source (2) emitting a Gaussian beam of light along a first optical path (11); - a sensor (3) capable of evaluating the effects of the electromagnetic interference of the first beam; - a generating means (2', 4) for generating a second Gaussian beam of light along a second optical path (12); - a second sensor (3') capable of evaluating the effects of the electromagnetic interference of the second beam; - a focusing lens (5,6), located on the first and/or the second optical path (11, 12), focusing the light beam at a distance f and defining an optical path (11',12') upstream; and - a means for routing (4',7) the second beam, capable of redirecting the second path (12') in the direction of the first path (11').

IPC Classes  ?

• G01B 9/02 - Interferometers
• G01B 11/24 - Measuring arrangements characterised by the use of optical techniques for measuring contours or curvatures
• G01B 11/30 - Measuring arrangements characterised by the use of optical techniques for measuring roughness or irregularity of surfaces

Abstract

Method for obtaining the profile of the external surface (22) of an environment (21) having a mid-plane (23), comprising the following steps: - obtaining two time signals A and B (1002), at any given moment, for the same geometric target on a read line of the external surface (22); - determining at least one Doppler frequency (2001) associated with each time signal A and B; - sampling each time signal A and B (2002) at a frequency greater than double the Doppler frequency in order to obtain a useful signal; - determining a useful signal envelope (2004) for each signal A and B; - carrying out a relative combination of the envelopes of each signal A and B (3001) to obtain a monotone one-to-one function F; - determining the profile of the external surface (3002) using a calibration of the function F.

IPC Classes  ?

• G01B 9/02 - Interferometers
• G01B 11/24 - Measuring arrangements characterised by the use of optical techniques for measuring contours or curvatures
• G01B 11/30 - Measuring arrangements characterised by the use of optical techniques for measuring roughness or irregularity of surfaces

Abstract

A process for manufacturing an abradable layer, includes compressing a powder composition including at least micrometric ceramic particles having a number-average form factor greater than or equal to 3, a mass content of said micrometric ceramic particles in the powder composition being greater than or equal to 85%, the form factor of a particle being defined as the ratio [largest dimension of the particle]/[largest cross-sectional dimension of the particle], and sintering the powder composition thus compressed to obtain the abradable layer, wherein a temperature imposed during sintering, the sintering time and the compression pressure applied are selected so as to obtain a volume porosity rate of the abradable layer greater than or equal to 20%.

IPC Classes  ?

• C23C 24/08 - Coating starting from inorganic powder by application of heat or pressure and heat
• C04B 41/00 - After-treatment of mortars, concrete, artificial stone or ceramicsTreatment of natural stone
• C04B 41/45 - Coating or impregnating
• B82Y 40/00 - Manufacture or treatment of nanostructures
• F01D 11/12 - Preventing or minimising internal leakage of working fluid, e.g. between stages for sealing space between rotor blade tips and stator using a rubstrip, e.g. erodible, deformable or resiliently biased part